Expansion of bariatric surgery in the UK ‘challenging’ due to significant upfront economic investmentExpanding the capacity of bariatric and metabolic surgery (BMS) capacity in England beyond a small proportion of the eligible population...
23 US states more than one in three adults has obesityThe latest CDC population data from 2023 show that in 23 states more than one in three adults (35%) has obesity. Before 2013, no state...
Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications
Expansion of bariatric surgery in the UK ‘challenging’ due to significant upfront economic investment
RefluxStop results in 90.9% reduction in GERD-HRQL scoreGerman investigators have reported that the RefluxStop implantable device for the management of gastroesophageal reflux disease (GERD)...
Journal watch 18/09/2024Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medicationsWeight reduction at one year is associated with the injectable semaglutide or liraglutide’s active agent, its dosage, treatment...
23 US states more than one in three adults has obesityThe latest CDC population data from 2023 show that in 23 states more than one in three adults (35%) has obesity. Before 2013, no state...
RefluxStop provides substantial clinical benefits for GERD patients with marginal budget impact on the health serviceIntroducing RefluxStop device (Implantica) as a treatment option for gastroesophageal reflux disease (GERD) patients treated within the...
Tirzepatide results in greater weight loss in women than menAll doses of tirzepatide consistently reduced body weight in women and men, but women experienced greater weight loss, according to post...
Semaglutide cardiovascular benefits are maintained in people with impaired kidney functionSemaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults...
Large-scale population analysis confirms safety profile of tirzepatideAn analysis of real-world evidence from the FDA Adverse Event Reporting System (FAERS) database of tirzepatide, presented at this year's...
Journal watch 11/09/2024Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Amycretin achieves 13% weight loss within three months with once-a-day tabletIndividuals who received a once-a-day oral weight loss drug, Amycretin developed by Novo Nordisk, lost up to 13% of their body weight...
Weight loss drug liraglutide is safe and effective in children under 12Liraglutide is safe and effective in children aged 6 to <12 years and those who took liraglutide for just over a year experienced a...
Insulin resistance is linked to over 30 diseases and to premature death in womenInsulin resistance is associated with 31 different diseases, and in women, is also linked to higher odds of early death, according to a...
FDA grants De Novo marketing authorisation to GT Metabolic Solutions for its magnet compression anastomosis technology
Olympus launches new Powerseal Sealer/Divider 5mm devices extending advanced bipolar surgical energy portfolio
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity